Status:
RECRUITING
Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patients With Structural Heart Disease
Lead Sponsor:
Assiut University
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
20-70 years
Phase:
PHASE1
Brief Summary
This is a prospective comparative study, conducted at Cardiology Department, Aswan University Hospital on AF patients with structural heart disease. Eplerenone 25 mg daily will be given and searching ...
Detailed Description
This is a prospective comparative study, conducted at Cardiology Department, Aswan University Hospital, on 100 patients with AF and structural heart disease. AF is confirmed by electrocardiography. Th...
Eligibility Criteria
Inclusion
- Patients with non-valvular AF who underwent cardioversion to sinus rhythm either medical, electrical or even spontaneously
Exclusion
- Patients with rheumatic heart disease.
- Thyroid dysfunction.
- Wolf-Parkinson-White (WPW) syndrome.
- Renal impairment.
- Hyperkalemia.
- Acute coronary syndrome.
- Pregnancy.
- Left ventricular (LV) dysfunction with ejection fraction (EF) less than 40%.
- On current use of eplerenone.
Key Trial Info
Start Date :
August 10 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 31 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06556732
Start Date
August 10 2024
End Date
August 31 2024
Last Update
August 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assiut University Heart Hospital
Asyut, Egypt, 71526